{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:46:00Z","timestamp":1793875560455,"version":"4.6.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Swiss National Science Foundation to Francesco Paneni","award":["310030_197557"],"award-info":[{"award-number":["310030_197557"]}]},{"name":"Swiss Heart Foundation to Francesco Paneni","award":["FF19045"],"award-info":[{"award-number":["FF19045"]}]},{"name":"European Union\u2013NextGenerationEU through the Italian Ministry of University and Research under PNRR-M4C2-I1.3","award":["PE_00000019 \u201cHEAL ITALIA\u201d to Stefano Taddei, CUP I53C22001440006"],"award-info":[{"award-number":["PE_00000019 \u201cHEAL ITALIA\u201d to Stefano Taddei, CUP I53C22001440006"]}]},{"name":"European Union\u2013NextGenerationEU through the Italian Ministry of University and Research under PNRR-M4C2-I1.3","award":["PE_00000019 \u201cHEAL ITALIA\u201d to Stefano Taddei, CUP I53C22001440006"],"award-info":[{"award-number":["PE_00000019 \u201cHEAL ITALIA\u201d to Stefano Taddei, CUP I53C22001440006"]}]},{"name":"European Union\u2013NextGenerationEU through the Italian Ministry of University and Research under PNRR-M4C2-I1.3","award":["PE_00000019 \u201cHEAL ITALIA\u201d to Stefano Taddei, CUP I53C22001440006"],"award-info":[{"award-number":["PE_00000019 \u201cHEAL ITALIA\u201d to Stefano Taddei, CUP I53C22001440006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02778-6","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T04:28:35Z","timestamp":1747888115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures"],"prefix":"10.1186","volume":"24","author":[{"given":"Nicola Riccardo","family":"Pugliese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tric\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Violet","family":"Bacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"De Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Dalpiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mengozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Virdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ghiadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2778_CR1","unstructured":"Collaborators GBDRF 2019 Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study. Lancet 2020, 396(10258):1223\u20131249."},{"issue":"7","key":"2778_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.115.016801","volume":"133","author":"D Aune","year":"2016","unstructured":"Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, Vatten LJ. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016;133(7):639\u201349.","journal-title":"Circulation"},{"issue":"9","key":"2778_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","volume":"69","author":"A Pandey","year":"2017","unstructured":"Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, Allen NB, de Lemos JA, Carnethon M, Greenland P, Berry JD. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017;69(9):1129\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2778_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa020245","volume":"347","author":"S Kenchaiah","year":"2002","unstructured":"Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305\u201313.","journal-title":"N Engl J Med"},{"key":"2778_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003921","author":"CE Ndumele","year":"2016","unstructured":"Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, Nambi V, Ballantyne CM, Solomon SD, Selvin E, Folsom AR, Coresh J. Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. 2016. https:\/\/doi.org\/10.1161\/JAHA.116.003921.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2778_CR6","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/ejhf.2308","volume":"23","author":"C Adamson","year":"2021","unstructured":"Adamson C, Jhund PS, Docherty KF, Belohlavek J, Chiang CE, Diez M, Drozdz J, Dukat A, Howlett J, Ljungman CEA, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021;23(10):1662\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"2778_CR7","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B, Desai AS, Alcocer Gamba MA, Al Habeeb W, Hernandez AF, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43(41):4406\u201317.","journal-title":"Eur Heart J"},{"issue":"1","key":"2778_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6\u201319.","journal-title":"Circulation"},{"issue":"12","key":"2778_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","volume":"142","author":"MS Khan","year":"2020","unstructured":"Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation. 2020;142(12):1205\u201318.","journal-title":"Circulation"},{"issue":"10437","key":"2778_CR10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstr\u00f8m SZ, Davies MJ, Hovingh GK, Kitzman DW, M\u00f8ller DV, Verma S, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635\u201348.","journal-title":"Lancet"},{"issue":"2","key":"2778_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00392-018-1302-7","volume":"108","author":"J Zhang","year":"2019","unstructured":"Zhang J, Begley A, Jackson R, Harrison M, Pellicori P, Clark AL, Cleland JGF. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis. Clin Res Cardiol. 2019;108(2):119\u201332.","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"2778_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/ijo.2013.203","volume":"38","author":"R Padwal","year":"2014","unstructured":"Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, Swedberg K, Maggioni A, Gamble G, Ariti C, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond). 2014;38(8):1110\u20134.","journal-title":"Int J Obes (Lond)"},{"key":"2778_CR13","doi-asserted-by":"publisher","first-page":"9040248","DOI":"10.1155\/2016\/9040248","volume":"2016","author":"EA Oga","year":"2016","unstructured":"Oga EA, Eseyin OR. The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes. 2016;2016:9040248.","journal-title":"J Obes"},{"issue":"1","key":"2778_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/heartjnl-2019-314770","volume":"106","author":"R Mahajan","year":"2020","unstructured":"Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A, Hendriks J, Linz D, Gallagher C, Kaye D, et al. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart. 2020;106(1):58\u201368.","journal-title":"Heart"},{"issue":"5","key":"2778_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-014-9425-z","volume":"19","author":"W Doehner","year":"2014","unstructured":"Doehner W. Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure? Heart Fail Rev. 2014;19(5):637\u201344.","journal-title":"Heart Fail Rev"},{"key":"2778_CR16","doi-asserted-by":"publisher","first-page":"e931808","DOI":"10.12659\/MSM.931808","volume":"27","author":"Y Liu","year":"2021","unstructured":"Liu Y, Song M, Huang L, Zhu G. \u201cObesity paradox\u201d in acute respiratory distress syndrome among patients undergoing cardiac surgery: a retrospective study. Med Sci Monit. 2021;27:e931808.","journal-title":"Med Sci Monit"},{"key":"2778_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","volume":"82","author":"PL Alebna","year":"2024","unstructured":"Alebna PL, Mehta A, Yehya A, daSilva-deAbreu A, Lavie CJ, Carbone S. Update on obesity, the obesity paradox, and obesity management in heart failure. Prog Cardiovasc Dis. 2024;82:34\u201342.","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"2778_CR18","doi-asserted-by":"publisher","first-page":"e002468","DOI":"10.1161\/JAHA.115.002468","volume":"5","author":"E Zamora","year":"2016","unstructured":"Zamora E, Diez-Lopez C, Lupon J, de Antonio M, Domingo M, Santesmases J, Troya MI, Diez-Quevedo C, Altimir S, Bayes-Genis A. Weight loss in obese patients with heart failure. J Am Heart Assoc. 2016;5(3):e002468.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2778_CR19","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1002\/ehf2.13619","volume":"8","author":"K Kamisaka","year":"2021","unstructured":"Kamisaka K, Kamiya K, Iwatsu K, Iritani N, Imoto S, Adachi T, Iida Y, Yamada S. collaborators F: impact of weight loss in patients with heart failure with preserved ejection fraction: results from the FLAGSHIP study. ESC Heart Fail. 2021;8(6):5293\u2013303.","journal-title":"ESC Heart Fail"},{"issue":"9363","key":"2778_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","volume":"361","author":"SD Anker","year":"2003","unstructured":"Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077\u201383.","journal-title":"Lancet"},{"issue":"21","key":"2778_CR21","doi-asserted-by":"publisher","first-page":"e022930","DOI":"10.1161\/JAHA.121.022930","volume":"10","author":"EC El Hajj","year":"2021","unstructured":"El Hajj EC, El Hajj MC, Sykes B, Lamicq M, Zile MR, Malcolm R, O\u2019Neil PM, Litwin SE. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10(21):e022930.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2778_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","volume":"8","author":"A Pandey","year":"2015","unstructured":"Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B, Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33\u201340.","journal-title":"Circ Heart Fail"},{"issue":"9","key":"2778_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/obr.12707","volume":"19","author":"K McDowell","year":"2018","unstructured":"McDowell K, Petrie MC, Raihan NA, Logue J. Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obes Rev. 2018;19(9):1189\u2013204.","journal-title":"Obes Rev"},{"issue":"2","key":"2778_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"ARG Look","year":"2013","unstructured":"Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354.","journal-title":"N Engl J Med"},{"issue":"15","key":"2778_CR25","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","volume":"143","author":"AG Doumouras","year":"2021","unstructured":"Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, Thabane L, Hong D, Yusuf S, Anvari M. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation. 2021;143(15):1468\u201380.","journal-title":"Circulation"},{"issue":"7","key":"2778_CR26","doi-asserted-by":"publisher","first-page":"e019323","DOI":"10.1161\/JAHA.120.019323","volume":"10","author":"G Hoskuldsdottir","year":"2021","unstructured":"Hoskuldsdottir G, Sattar N, Miftaraj M, Naslund I, Ottosson J, Franzen S, Svensson AM, Eliasson B. Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: a nationwide, matched, observational cohort study. J Am Heart Assoc. 2021;10(7):e019323.","journal-title":"J Am Heart Assoc"},{"key":"2778_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ahj.2020.09.007","volume":"230","author":"V Blumer","year":"2020","unstructured":"Blumer V, Greene SJ, Ortiz M, Kittipibul V, Hernandez GA, Fudim M, Lemor A, Mentz RJ, Vest AR. In-hospital outcomes after bariatric surgery in patients with heart failure. Am Heart J. 2020;230:59\u201362.","journal-title":"Am Heart J"},{"issue":"2","key":"2778_CR28","doi-asserted-by":"publisher","first-page":"e010453","DOI":"10.1161\/CIRCHEARTFAILURE.122.010453","volume":"17","author":"A Mentias","year":"2024","unstructured":"Mentias A, Desai MY, Aminian A, Patel KV, Keshvani N, Verma S, Cho L, Jacob M, Alvarez P, Lincoff AM, et al. Trends and Outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity. Circ Heart Fail. 2024;17(2):e010453.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"2778_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jacc.2015.12.016","volume":"67","author":"YJ Shimada","year":"2016","unstructured":"Shimada YJ, Tsugawa Y, Brown DFM, Hasegawa K. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based self-controlled series. J Am Coll Cardiol. 2016;67(8):895\u2013903.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2778_CR30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905\u201317.","journal-title":"N Engl J Med"},{"issue":"17","key":"2778_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMp1211277","volume":"367","author":"E Colman","year":"2012","unstructured":"Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA\u2019s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"2778_CR32","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.15077","volume":"25","author":"M Bluher","year":"2023","unstructured":"Bluher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, Pietilainen KH, Schnell O, Tonchevska E, Wilding JPH. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25(8):2058\u201372.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2778_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4239\/wjd.v15.i5.818","volume":"15","author":"L Nesti","year":"2024","unstructured":"Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth? World J Diabetes. 2024;15(5):818\u201322.","journal-title":"World J Diabetes"},{"issue":"10","key":"2778_CR34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00125-023-05973-w","volume":"66","author":"A Solini","year":"2023","unstructured":"Solini A, Trico D, Del Prato S. Incretins and cardiovascular disease: to the heart of type 2 diabetes? Diabetologia. 2023;66(10):1820\u201331.","journal-title":"Diabetologia"},{"issue":"10","key":"2778_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2778_CR36","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"24","key":"2778_CR37","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2778_CR38","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"8","key":"2778_CR39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","volume":"110","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen Y-T, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955\u201361.","journal-title":"Circulation"},{"issue":"3","key":"2778_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1161\/CIRCHEARTFAILURE.108.766402","volume":"1","author":"I Poornima","year":"2008","unstructured":"Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive. Heart Failure-Prone Rat Circ: Heart Failure. 2008;1(3):153\u201360.","journal-title":"Heart Failure-Prone Rat Circ: Heart Failure"},{"issue":"1","key":"2778_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","volume":"127","author":"MH Noyan-Ashraf","year":"2013","unstructured":"Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li R-K, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A Glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127(1):74\u201385.","journal-title":"Circulation"},{"issue":"9","key":"2778_CR42","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","volume":"117","author":"C Withaar","year":"2021","unstructured":"Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Sillj\u00e9 HHW, Schouten EM, Dokter MM, Voors AA, Westenbrink BD, Lam CSP, de Boer RA. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res. 2021;117(9):2108\u201324.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"2778_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jchf.2016.01.008","volume":"4","author":"JJ Lepore","year":"2016","unstructured":"Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC: Heart Failure. 2016;4(7):559\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2016.01.008.","journal-title":"JACC: Heart Failure"},{"issue":"2","key":"2778_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12350-017-1000-2","volume":"26","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, Jorsal A, Iversen P, Tolbod LP, Bouchelouche K, S\u00f8rensen J, Harms HJ, Flyvbjerg A, Tarnow L, Kistorp C, et al. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: a double-blind, randomized, placebo-controlled LIVE sub-study. J Nucl Cardiol. 2019;26(2):585\u201397.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"2778_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","volume":"20","author":"A Natali","year":"2021","unstructured":"Natali A, Nesti L, Trico D, Ferrannini E. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol. 2021;20(1):196.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2778_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","volume":"145","author":"CSP Lam","year":"2022","unstructured":"Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, Del Prato S, Lopes RD, Niemoeller E, Khurmi NS, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145(8):565\u201374.","journal-title":"Circulation"},{"key":"2778_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.07.006","author":"R Patel","year":"2024","unstructured":"Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, et al. GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 Inhibitors. JACC Heart Failure. 2024. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.006.","journal-title":"JACC Heart Failure"},{"issue":"6","key":"2778_CR48","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/dom.14997","volume":"25","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Saraiva F, Sharma A, Vasques-N\u00f3voa F, Ang\u00e9lico-Gon\u00e7alves A, Leite AR, Borges-Canha M, Carvalho D, Packer M, Zannad F, et al. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials. Diabetes Obes Metab. 2023;25(6):1495\u2013502.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2778_CR49","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00392-023-02362-6","volume":"113","author":"A Villaschi","year":"2024","unstructured":"Villaschi A, Ferrante G, Cannata F, Pini D, Pagnesi M, Corrada E, Reimers B, Mehran R, Federici M, Savarese G, et al. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin Res Cardiol. 2024;113(6):898\u2013909.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2778_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2016","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, Nilsson B, M\u00f8ller JE, Hjort J, Rasmussen J, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2016;19(1):69\u201377.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2778_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Michael Felker G, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500. https:\/\/doi.org\/10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"issue":"7","key":"2778_CR52","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","volume":"29","author":"JS Neves","year":"2023","unstructured":"Neves JS, Packer M, Ferreira JP. Increased risk of heart failure hospitalization With GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials. J Cardiac Fail. 2023;29(7):1107\u20139.","journal-title":"J Cardiac Fail"},{"issue":"4","key":"2778_CR53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ejhf.240","volume":"17","author":"P Rossignol","year":"2015","unstructured":"Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail. 2015;17(4):424\u201333.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2778_CR54","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, Nissen SD, Soattin L, Sorrentino A, Vega ET, Linz B, Eggertsen CHE, Mulvey J, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120(12):1427\u201341.","journal-title":"Cardiovasc Res"},{"issue":"10454","key":"2778_CR55","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u201386.","journal-title":"Lancet"},{"key":"2778_CR56","unstructured":"Deanfield J: Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: a pre-specified analysis from the SELECT trial. In: 2024 ESC Heart Failure Congress: 2024; Lisbon; 2024."},{"issue":"15","key":"2778_CR57","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"21","key":"2778_CR58","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"10454","key":"2778_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(24)01598-8","volume":"404","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M. GLP-1 receptor agonists in heart failure. Lancet. 2024;404(10454):727\u20139.","journal-title":"Lancet"},{"issue":"4","key":"2778_CR60","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/ejhf.3184","volume":"26","author":"A Peikert","year":"2024","unstructured":"Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Foa A, Desai AS, Jhund PS, Carberry J, Lam CSP, Kosiborod MN, et al. Dapagliflozin in patients with heart failure and previous myocardial infarction: a participant-level pooled analysis of DAPA-HF and DELIVER. Eur J Heart Fail. 2024;26(4):912\u201324.","journal-title":"Eur J Heart Fail"},{"key":"2778_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae322","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehae322.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10456","key":"2778_CR62","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361.","journal-title":"Lancet"},{"issue":"5","key":"2778_CR63","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2024","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2024;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"8","key":"2778_CR64","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1111\/dom.15631","volume":"26","author":"KL Jones","year":"2024","unstructured":"Jones KL, Marathe CS, Wu T, Rayner CK, Nauck M, Horowitz M. Getting the measure of the pressure: optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure. Diabetes Obes Metab. 2024;26(8):3003\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"10456","key":"2778_CR65","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(24)01763-X","volume":"404","author":"C Hage","year":"2024","unstructured":"Hage C. GLP-1 receptor agonists in heart failure: how far to expand use? The Lancet. 2024;404(10456):909\u201311.","journal-title":"The Lancet"},{"issue":"3","key":"2778_CR66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jchf.2017.11.011","volume":"6","author":"TM Powell-Wiley","year":"2018","unstructured":"Powell-Wiley TM, Ngwa J, Kebede S, Di L, Schulte PJ, Bhatt DL, Yancy C, Fonarow GC, Albert MA. Impact of body mass index on heart failure by race\/ethnicity from the get with\u00a0the guidelines\u2013heart failure (GWTG\u2013HF) registry. JACC: Heart Failure. 2018;6(3):233\u201342. https:\/\/doi.org\/10.1016\/j.jchf.2017.11.011.","journal-title":"JACC: Heart Failure"},{"issue":"4","key":"2778_CR67","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.3112","volume":"26","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Vitale C, Guidetti F, Benson L, Braunschweig F, Dahlstr\u00f6m U, Melin M, Rosano GMC, Lund LH, Metra M, Savarese G. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024;26(4):854\u201368.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2778_CR68","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"1","key":"2778_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2024.6586","volume":"332","author":"C Conte","year":"2024","unstructured":"Conte C, Hall KD, Klein S. Is weight loss\u2013induced muscle mass loss clinically relevant? JAMA. 2024;332(1):9. https:\/\/doi.org\/10.1001\/jama.2024.6586.","journal-title":"JAMA"},{"issue":"4","key":"2778_CR70","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cardfail.2024.01.005","volume":"30","author":"E Driggin","year":"2024","unstructured":"Driggin E, Goyal P. Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF. J Cardiac Fail. 2024;30(4):610\u20132.","journal-title":"J Cardiac Fail"},{"key":"2778_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, Stanford FC, Batterham RL, Farooqi IS, Farpour-Lambert NJ, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2778_CR72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/dom.15324","volume":"26","author":"L Nesti","year":"2024","unstructured":"Nesti L, Pugliese NR, Santoni L, Armenia S, Chiriaco M, Sacchetta L, De Biase N, Del Punta L, Masi S, Trico D, Natali A. Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance. Diabetes Obes Metab. 2024;26(1):351\u201361.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2778_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/dom.14861","volume":"25","author":"L Nesti","year":"2023","unstructured":"Nesti L, Pugliese NR, Chiriaco M, Trico D, Baldi S, Natali A. Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function. Diabetes Obes Metab. 2023;25(1):177\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2778_CR74","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/obr.12358","volume":"17","author":"SB Heymsfield","year":"2016","unstructured":"Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM Jr. Why are there race\/ethnic differences in adult body mass index-adiposity relationships? Quant Crit Rev Obes Rev. 2016;17(3):262\u201375.","journal-title":"Quant Crit Rev Obes Rev"},{"issue":"5","key":"2778_CR75","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ijo.2010.5","volume":"34","author":"DO Okorodudu","year":"2010","unstructured":"Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010;34(5):791\u20139.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"2778_CR76","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pcad.2018.06.004","volume":"61","author":"ME Piche","year":"2018","unstructured":"Piche ME, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018;61(2):103\u201313.","journal-title":"Prog Cardiovasc Dis"},{"issue":"Suppl 3","key":"2778_CR77","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1038\/ijo.2008.87","volume":"32","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes (Lond). 2008;32(Suppl 3):S56-59.","journal-title":"Int J Obes (Lond)"},{"issue":"13","key":"2778_CR78","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, Kober L, Rouleau JL, Swedberg K, Zile MR, Solomon SD, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44(13):1136\u201353.","journal-title":"Eur Heart J"},{"key":"2778_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.1196","author":"J Butt","year":"2024","unstructured":"Butt J, Thune JJ, Nielsen JC, Gustafsson F, Bruun NE, Eiskjaer H, Brandes A, Hassager C, Svendsen JH, Torp-Pedersen C, Schou M, Pehrson S, Packer M, Mcmurray JJV, Koeber L. Anthropometric measures and long-term mortality in heart failure with reduced ejection: debunking the obesity paradox. European Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.1196.","journal-title":"European Heart J"},{"issue":"10","key":"2778_CR80","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3390\/nu15102254","volume":"15","author":"GA Bray","year":"2023","unstructured":"Bray GA. Beyond BMI. Nutrients. 2023;15(10):2254. https:\/\/doi.org\/10.3390\/nu15102254.","journal-title":"Nutrients"},{"issue":"9","key":"2778_CR81","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"2778_CR82","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","volume":"6","author":"VN Rao","year":"2018","unstructured":"Rao VN, Zhao D, Allison MA, Guallar E, Sharma K, Criqui MH, Cushman M, Blumenthal RS, Michos ED. Adiposity and incident heart failure and its subtypes: MESA (Multi-ethnic study of atherosclerosis). JACC Heart Fail. 2018;6(12):999\u20131007.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"2778_CR83","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H. Obesity management task force of the european association for the study of obesity: European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402\u201324.","journal-title":"Obes Facts"},{"issue":"2","key":"2778_CR84","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0008-6363(99)00263-1","volume":"45","author":"GJ van der Vusse","year":"2000","unstructured":"van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000;45(2):279\u201393.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"2778_CR85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nrendo.2015.58","volume":"11","author":"G Iacobellis","year":"2015","unstructured":"Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11(6):363\u201371.","journal-title":"Nat Rev Endocrinol"},{"issue":"18","key":"2778_CR86","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","volume":"118","author":"NR Pugliese","year":"2023","unstructured":"Pugliese NR, Pellicori P, Filidei F, De Biase N, Maffia P, Guzik TJ, Masi S, Taddei S, Cleland JGF. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res. 2023;118(18):3536\u201355.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"2778_CR87","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1210\/jc.2009-0571","volume":"94","author":"HS Sacks","year":"2009","unstructured":"Sacks HS, Fain JN, Holman B, Cheema P, Chary A, Parks F, Karas J, Optican R, Bahouth SW, Garrett E, et al. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. J Clin Endocrinol Metab. 2009;94(9):3611\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2778_CR88","doi-asserted-by":"publisher","first-page":"9628","DOI":"10.1038\/s41598-018-27376-3","volume":"8","author":"HP Fainberg","year":"2018","unstructured":"Fainberg HP, Birtwistle M, Alagal R, Alhaddad A, Pope M, Davies G, Woods R, Castellanos M, May ST, Ortori CA, et al. Transcriptional analysis of adipose tissue during development reveals depot-specific responsiveness to maternal dietary supplementation. Sci Rep. 2018;8(1):9628.","journal-title":"Sci Rep"},{"issue":"3","key":"2778_CR89","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/j.2040-4603.2017.tb00767.x","volume":"7","author":"B Gaborit","year":"2017","unstructured":"Gaborit B, Sengenes C, Ancel P, Jacquier A, Dutour A. Role of epicardial adipose tissue in health and disease: a matter of fat? Compr Physiol. 2017;7(3):1051\u201382.","journal-title":"Compr Physiol"},{"issue":"3","key":"2778_CR90","doi-asserted-by":"publisher","first-page":"718","DOI":"10.2337\/db08-1098","volume":"58","author":"M Pasarica","year":"2009","unstructured":"Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009;58(3):718\u201325.","journal-title":"Diabetes"},{"issue":"1","key":"2778_CR91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.111.027813","volume":"124","author":"GH Goossens","year":"2011","unstructured":"Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clement K, Blaak EE. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation. 2011;124(1):67\u201376.","journal-title":"Circulation"},{"issue":"8","key":"2778_CR92","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jchf.2020.06.003","volume":"8","author":"TM Gorter","year":"2020","unstructured":"Gorter TM, van Woerden G, Rienstra M, Dickinson MG, Hummel YM, Voors AA, Hoendermis ES, van Veldhuisen DJ. Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(8):667\u201376.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"2778_CR93","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","volume":"8","author":"KE Koepp","year":"2020","unstructured":"Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(8):657\u201366.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"2778_CR94","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jacc.2020.07.017","volume":"76","author":"CJ Nalliah","year":"2020","unstructured":"Nalliah CJ, Bell JR, Raaijmakers AJA, Waddell HM, Wells SP, Bernasochi GB, Montgomery MK, Binny S, Watts T, Joshi SB, et al. Epicardial adipose tissue accumulation confers atrial conduction abnormality. J Am Coll Cardiol. 2020;76(10):1197\u2013211.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2778_CR95","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/clc.23644","volume":"44","author":"G van Woerden","year":"2021","unstructured":"van Woerden G, van Veldhuisen DJ, Gorter TM, van Empel VPM, Hemels MEW, Hazebroek EJ, van Veldhuisen SL, Willems TP, Rienstra M, Westenbrink BD. Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid-range and preserved ejection fraction. Clin Cardiol. 2021;44(7):987\u201393.","journal-title":"Clin Cardiol"},{"key":"2778_CR96","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.atherosclerosis.2019.01.033","volume":"284","author":"Z Liu","year":"2019","unstructured":"Liu Z, Wang S, Wang Y, Zhou N, Shu J, Stamm C, Jiang M, Luo F. Association of epicardial adipose tissue attenuation with coronary atherosclerosis in patients with a high risk of coronary artery disease. Atherosclerosis. 2019;284:230\u20136.","journal-title":"Atherosclerosis"},{"issue":"9","key":"2778_CR97","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/ehjci\/jeac092","volume":"23","author":"J Mancio","year":"2022","unstructured":"Mancio J, Sousa-Nunes F, Martins R, Fragao-Marques M, Conceicao G, Pessoa-Amorim G, Barros AS, Santa C, Ferreira W, Carvalho M, et al. Decoding the radiomic and proteomic phenotype of epicardial adipose tissue associated with adverse left atrial remodelling and post-operative atrial fibrillation in aortic stenosis. Eur Heart J Cardiovasc Imag. 2022;23(9):1248\u201359.","journal-title":"Eur Heart J Cardiovasc Imag"},{"issue":"12","key":"2778_CR98","doi-asserted-by":"publisher","first-page":"8445","DOI":"10.1007\/s00330-023-09878-5","volume":"33","author":"J Chan","year":"2023","unstructured":"Chan J, Thakur U, Tan S, Muthalaly RG, Thakkar H, Goel V, Cheen YC, Dey D, Brown AJ, Wong DTL, Nerlekar N. Inter-software and inter-scan variability in measurement of epicardial adipose tissue: a three-way comparison of a research-specific, a freeware and a coronary application software platform. Eur Radiol. 2023;33(12):8445\u201353.","journal-title":"Eur Radiol"},{"issue":"21","key":"2778_CR99","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","volume":"77","author":"S Kenchaiah","year":"2021","unstructured":"Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, Burke GL, McClelland RL, Arai AE, Bluemke DA. Pericardial fat and the risk of heart failure. J Am Coll Cardiol. 2021;77(21):2638\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2778_CR100","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.amjcard.2014.08.037","volume":"114","author":"R Fontes-Carvalho","year":"2014","unstructured":"Fontes-Carvalho R, Fontes-Oliveira M, Sampaio F, Mancio J, Bettencourt N, Teixeira M, Rocha Goncalves F, Gama V, Leite-Moreira A. Influence of epicardial and visceral fat on left ventricular diastolic and systolic functions in patients after myocardial infarction. Am J Cardiol. 2014;114(11):1663\u20139.","journal-title":"Am J Cardiol"},{"issue":"17","key":"2778_CR101","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.jacc.2010.11.045","volume":"57","author":"CX Wong","year":"2011","unstructured":"Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, Leong DP, Lau DH, Middeldorp ME, Roberts-Thomson KC, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2778_CR102","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L, Mengozzi A, Virdis A, Nesti L, Taddei S, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23(11):1858\u201371.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2778_CR103","doi-asserted-by":"publisher","first-page":"e009238","DOI":"10.1161\/CIRCHEARTFAILURE.121.009238","volume":"15","author":"G van Woerden","year":"2022","unstructured":"van Woerden G, van Veldhuisen DJ, Manintveld OC, van Empel VPM, Willems TP, de Boer RA, Rienstra M, Westenbrink BD, Gorter TM. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction. Circ Heart Fail. 2022;15(3):e009238.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2778_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1532-429X-12-40","volume":"12","author":"C Doesch","year":"2010","unstructured":"Doesch C, Haghi D, Fluchter S, Suselbeck T, Schoenberg SO, Michaely H, Borggrefe M, Papavassiliu T. Epicardial adipose tissue in patients with heart failure. J Cardiovasc Magn Reson. 2010;12(1):40.","journal-title":"J Cardiovasc Magn Reson"},{"key":"2778_CR105","doi-asserted-by":"publisher","first-page":"1291537","DOI":"10.1155\/2016\/1291537","volume":"2016","author":"J Salazar","year":"2016","unstructured":"Salazar J, Luzardo E, Mejias JC, Rojas J, Ferreira A, Rivas-Rios JR, Bermudez V. Epicardial fat: physiological, pathological, and therapeutic implications. Cardiol Res Pract. 2016;2016:1291537.","journal-title":"Cardiol Res Pract"},{"issue":"10","key":"2778_CR106","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","volume":"72","author":"J Tromp","year":"2018","unstructured":"Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2018;72(10):1081\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2778_CR107","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/ejhf.1617","volume":"22","author":"CK Wu","year":"2020","unstructured":"Wu CK, Lee JK, Hsu JC, Su MM, Wu YF, Lin TT, Lan CW, Hwang JJ, Lin LY. Myocardial adipose deposition and the development of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):445\u201354.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"2778_CR108","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/ejhf.2363","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp J, Packer M, Lam CS. The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. Eur J Heart Fail. 2021;23(11):1872\u20134.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2778_CR109","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ejhf.1956","volume":"22","author":"VN Rao","year":"2020","unstructured":"Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(9):1540\u201350.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2778_CR110","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ejhf.792","volume":"19","author":"A Olivier","year":"2017","unstructured":"Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJV, Swedberg K, Van Veldhuisen DJ, Collier TJ, Pocock SJ, et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Eur J Heart Fail. 2017;19(9):1186\u201397.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2778_CR111","doi-asserted-by":"publisher","first-page":"e13136","DOI":"10.1111\/obr.13136","volume":"22","author":"N Launbo","year":"2021","unstructured":"Launbo N, Zobel EH, von Scholten BJ, Faerch K, Jorgensen PG, Christensen RH. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: a systematic review and meta-analysis. Obes Rev. 2021;22(1):e13136.","journal-title":"Obes Rev"},{"key":"2778_CR112","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijcard.2019.04.039","volume":"292","author":"E Dozio","year":"2019","unstructured":"Dozio E, Vianello E, Malavazos AE, Tacchini L, Schmitz G, Iacobellis G, Corsi Romanelli MM. Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk? Int J Cardiol. 2019;292:218\u201324.","journal-title":"Int J Cardiol"},{"issue":"7","key":"2778_CR113","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025;85(7):699\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2778_CR114","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12933-023-01738-2","volume":"22","author":"VA Myasoedova","year":"2023","unstructured":"Myasoedova VA, Parisi V, Moschetta D, Valerio V, Conte M, Massaiu I, Bozzi M, Celeste F, Leosco D, Iaccarino G, et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):23.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"2778_CR115","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2012.06.016","volume":"60","author":"B Gaborit","year":"2012","unstructured":"Gaborit B, Jacquier A, Kober F, Abdesselam I, Cuisset T, Boullu-Ciocca S, Emungania O, Alessi MC, Clement K, Bernard M, Dutour A. Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol. 2012;60(15):1381\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2778_CR116","doi-asserted-by":"publisher","first-page":"1092777","DOI":"10.3389\/fendo.2023.1092777","volume":"14","author":"JA Henry","year":"2023","unstructured":"Henry JA, Abdesselam I, Deal O, Lewis AJ, Rayner J, Bernard M, Dutour A, Gaborit B, Kober F, Soghomonian A, et al. Changes in epicardial and visceral adipose tissue depots following bariatric surgery and their effect on cardiac geometry. Front Endocrinol (Lausanne). 2023;14:1092777.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"17","key":"2778_CR117","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/eurjpc\/zwac179","volume":"29","author":"AB Gevaert","year":"2022","unstructured":"Gevaert AB, Wood N, Boen JRA, Davos CH, Hansen D, Hanssen H, Krenning G, Moholdt T, Osto E, Paneni F, et al. Epigenetics in the primary and secondary prevention of cardiovascular disease: influence of exercise and nutrition. Eur J Prev Cardiol. 2022;29(17):2183\u201399.","journal-title":"Eur J Prev Cardiol"},{"key":"2778_CR118","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.atherosclerosis.2018.09.029","volume":"281","author":"S Costantino","year":"2019","unstructured":"Costantino S, Mohammed SA, Ambrosini S, Paneni F. Epigenetic processing in cardiometabolic disease. Atherosclerosis. 2019;281:150\u20138.","journal-title":"Atherosclerosis"},{"issue":"15","key":"2778_CR119","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1089\/ars.2020.8040","volume":"34","author":"S Masi","year":"2021","unstructured":"Masi S, Ambrosini S, Mohammed SA, Sciarretta S, Luscher TF, Paneni F, Costantino S. Epigenetic remodeling in obesity-related vascular disease. Antioxid Redox Signal. 2021;34(15):1165\u201399.","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"2778_CR120","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1053\/j.gastro.2017.01.054","volume":"152","author":"T Fall","year":"2017","unstructured":"Fall T, Mendelson M, Speliotes EK. Recent advances in human genetics and epigenetics of adiposity: pathway to precision medicine? Gastroenterology. 2017;152(7):1695\u2013706.","journal-title":"Gastroenterology"},{"issue":"1","key":"2778_CR121","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3945\/an.113.004705","volume":"5","author":"JA Martinez","year":"2014","unstructured":"Martinez JA, Milagro FI, Claycombe KJ, Schalinske KL. Epigenetics in adipose tissue, obesity, weight loss, and diabetes. Adv Nutr. 2014;5(1):71\u201381.","journal-title":"Adv Nutr"},{"issue":"6627","key":"2778_CR122","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.abj8894","volume":"379","author":"M Hata","year":"2023","unstructured":"Hata M, Andriessen E, Hata M, Diaz-Marin R, Fournier F, Crespo-Garcia S, Blot G, Juneau R, Pilon F, Dejda A, et al. Past history of obesity triggers persistent epigenetic changes in innate immunity and exacerbates neuroinflammation. Science. 2023;379(6627):45\u201362.","journal-title":"Science"},{"issue":"8042","key":"2778_CR123","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-08165-7","volume":"636","author":"LC Hinte","year":"2024","unstructured":"Hinte LC, Castellano-Castillo D, Ghosh A, Melrose K, Gasser E, Noe F, Massier L, Dong H, Sun W, Hoffmann A, et al. Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature. 2024;636(8042):457\u201365.","journal-title":"Nature"},{"issue":"9","key":"2778_CR124","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.2337\/db17-0294","volume":"66","author":"S Costantino","year":"2017","unstructured":"Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, Tanese L, Russo G, Pitocco D, Lanza GA, et al. Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels. Diabetes. 2017;66(9):2472\u201382.","journal-title":"Diabetes"},{"issue":"1","key":"2778_CR125","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-024-02195-1","volume":"23","author":"MC Vinci","year":"2024","unstructured":"Vinci MC, Costantino S, Damiano G, Rurali E, Rinaldi R, Vigorelli V, Sforza A, Carulli E, Pirola S, Mastroiacovo G, et al. Persistent epigenetic signals propel a senescence-associated secretory phenotype and trained innate immunity in CD34(+) hematopoietic stem cells from diabetic patients. Cardiovasc Diabetol. 2024;23(1):107.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2778_CR126","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ijo.2015.221","volume":"40","author":"KH Pietilainen","year":"2016","unstructured":"Pietilainen KH, Ismail K, Jarvinen E, Heinonen S, Tummers M, Bollepalli S, Lyle R, Muniandy M, Moilanen E, Hakkarainen A, et al. DNA methylation and gene expression patterns in adipose tissue differ significantly within young adult monozygotic BMI-discordant twin pairs. Int J Obes (Lond). 2016;40(4):654\u201361.","journal-title":"Int J Obes (Lond)"},{"issue":"13\u201324","key":"2778_CR127","first-page":"e15","volume":"178","author":"AB Crujeiras","year":"2016","unstructured":"Crujeiras AB, Diaz-Lagares A, Moreno-Navarrete JM, Sandoval J, Hervas D, Gomez A, Ricart W, Casanueva FF, Esteller M, Fernandez-Real JM. Genome-wide DNA methylation pattern in visceral adipose tissue differentiates insulin-resistant from insulin-sensitive obese subjects. Transl Res. 2016;178(13\u201324):e15.","journal-title":"Transl Res"},{"issue":"7635","key":"2778_CR128","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature20784","volume":"541","author":"S Wahl","year":"2017","unstructured":"Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y, et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature. 2017;541(7635):81\u20136.","journal-title":"Nature"},{"issue":"47","key":"2778_CR129","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1093\/eurheartj\/ehx568","volume":"39","author":"S Costantino","year":"2018","unstructured":"Costantino S, Libby P, Kishore R, Tardif JC, El-Osta A, Paneni F. Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. Eur Heart J. 2018;39(47):4150\u20138.","journal-title":"Eur Heart J"},{"issue":"8","key":"2778_CR130","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41569-024-01001-5","volume":"21","author":"A Caporali","year":"2024","unstructured":"Caporali A, Anwar M, Devaux Y, Katare R, Martelli F, Srivastava PK, Pedrazzini T, Emanueli C. Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease. Nat Rev Cardiol. 2024;21(8):556\u201373.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2778_CR131","doi-asserted-by":"publisher","first-page":"e000062","DOI":"10.1161\/HCG.0000000000000062","volume":"13","author":"S Das","year":"2020","unstructured":"Das S, Shah R, Dimmeler S, Freedman JE, Holley C, Lee JM, Moore K, Musunuru K, Wang DZ, Xiao J, et al. Noncoding RNAs in cardiovascular disease: current knowledge, tools and technologies for investigation, and future directions: a scientific statement from the american heart association. Circ Genom Precis Med. 2020;13(4):e000062.","journal-title":"Circ Genom Precis Med"},{"issue":"4","key":"2778_CR132","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2023.05.031","volume":"82","author":"MC Carena","year":"2023","unstructured":"Carena MC, Badi I, Polkinghorne M, Akoumianakis I, Psarros C, Wahome E, Kotanidis CP, Akawi N, Antonopoulos AS, Chauhan J, et al. Role of human epicardial adipose tissue-derived miR-92a-3p in myocardial redox state. J Am Coll Cardiol. 2023;82(4):317\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2778_CR133","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.hroo.2023.10.007","volume":"4","author":"AC Ernault","year":"2023","unstructured":"Ernault AC, de Winter R, Fabrizi B, Bracht JWP, Hau C, van Amersfoorth SCM, Meulendijks ER, Tijsen AJ, Ortega LC, van der Made I, et al. MicroRNAs in extracellular vesicles released from epicardial adipose tissue promote arrhythmogenic conduction slowing. Heart Rhythm O2. 2023;4(12):805\u201314. https:\/\/doi.org\/10.1016\/j.hroo.2023.10.007.","journal-title":"Heart Rhythm O2"},{"key":"2778_CR134","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fcvm.2019.00115","volume":"6","author":"KV Tran","year":"2019","unstructured":"Tran KV, Majka J, Sanghai S, Sardana M, Lessard D, Milstone Z, Tanriverdi K, Freedman JE, Fitzgibbons TP, McManus D. Micro-RNAs are related to epicardial adipose tissue in participants with atrial fibrillation: data from the mirhythm study. Front Cardiovasc Med. 2019;6:115.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2778_CR135","doi-asserted-by":"publisher","first-page":"103726","DOI":"10.1016\/j.numecd.2024.08.019","volume":"35","author":"G Iacobellis","year":"2024","unstructured":"Iacobellis G, Goldberger JJ, Lamelas J, Martinez CA, Sterling CM, Bodenstab M, Frasca D. Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control. Nutr Metab Cardiovasc Dis. 2024;35(2):103726.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"2778_CR136","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12933-023-02057-2","volume":"22","author":"S Costantino","year":"2023","unstructured":"Costantino S, Mengozzi A, Velagapudi S, Mohammed SA, Gorica E, Akhmedov A, Mongelli A, Pugliese NR, Masi S, Virdis A, et al. Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy. Cardiovasc Diabetol. 2023;22(1):312.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2778_CR137","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/CIRCRESAHA.122.320888","volume":"131","author":"A Mengozzi","year":"2022","unstructured":"Mengozzi A, Costantino S, Paneni F, Duranti E, Nannipieri M, Mancini R, Lai M, La Rocca V, Puxeddu I, Antonioli L, et al. Targeting SIRT1 rescues age- and obesity-induced microvascular dysfunction in Ex vivo human vessels. Circ Res. 2022;131(6):476\u201391.","journal-title":"Circ Res"},{"key":"2778_CR138","doi-asserted-by":"publisher","first-page":"107155","DOI":"10.1016\/j.phrs.2024.107155","volume":"203","author":"C Tian","year":"2024","unstructured":"Tian C, Huang R, Xiang M. SIRT1: harnessing multiple pathways to hinder NAFLD. Pharmacol Res. 2024;203:107155.","journal-title":"Pharmacol Res"},{"issue":"12","key":"2778_CR139","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"15","key":"2778_CR140","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Treppendahl MB, Verma S, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"17","key":"2778_CR141","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JFE, MacIsaac RJ, Kosiborod MN, Kamenov Z, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol. 2024;84(17):1615\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2778_CR142","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"19","key":"2778_CR143","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"9","key":"2778_CR144","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"key":"2778_CR145","unstructured":"Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial [https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=171480]"},{"issue":"2","key":"2778_CR146","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"2778_CR147","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2778_CR148","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"13","key":"2778_CR149","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"2778_CR150","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","volume":"28","author":"CT Ruff","year":"2022","unstructured":"Ruff CT, Baron M, Im K, O\u2019Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022;28(1):89\u201395.","journal-title":"Nat Med"},{"issue":"23","key":"2778_CR151","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L, Wei X, Lewis EF, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02778-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02778-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02778-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:03:11Z","timestamp":1747893791000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02778-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2778"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02778-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DT reports receiving fees for serving on advisory boards from Amarin, Boehringer Ingelheim and Novo Nordisk, lecture fees from Eli Lilly, and travel support from AstraZeneca. FP reports receiving fees for serving on advisory boards from Novo Nordisk. He also serves as Guest Editor for the thematic collection to which the current manuscript has been submitted; as such, has not been involved in the peer review process for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}